	US 12,281,175 B2
	Binding molecules for BCMA and CD3
Peter Kufer, Munich (DE); Tobias Raum, Munich (DE); Patrick Hoffmann, Munich (DE); Roman Kischel, Munich (DE); Ralf Lutterbuese, Munich (DE); Doris Rau, Munich (DE); Paul Adam, Munich (DE); Eric Borges, Munich (DE); Barbara Hebeis, Munich (DE); and Susanne Hipp, Munich (DE)
Assigned to Amgen Inc., Thousand Oaks, CA (US); and Amgen Research (Munich) GmbH, Munich (DE)
Filed by Amgen Inc., Thousand Oaks, CA (US); and Amgen Research (Munich) GmbH, Munich (DE)
Filed on Sep. 3, 2020, as Appl. No. 17/011,849.
Application 17/011,849 is a continuation of application No. 14/358,511, granted, now 10,766,969, previously published as PCT/EP2012/072699, filed on Nov. 15, 2012.
Claims priority of provisional application 61/651,486, filed on May 24, 2012.
Claims priority of provisional application 61/651,474, filed on May 24, 2012.
Claims priority of provisional application 61/560,183, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,162, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,149, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,144, filed on Nov. 15, 2011.
Claims priority of provisional application 61/560,178, filed on Nov. 15, 2011.
Prior Publication US 2022/0064336 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/468 (2013.01) [A61K 39/0005 (2013.01); C07K 14/70578 (2013.01); C07K 16/2809 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/575 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/43 (2013.01)]

16 Claims

1. A method of inducing cytotoxicity in a cell expressing human B cell maturation antigen (BCMA) comprising:

contacting the cell with a bispecific binding molecule comprising:

a first binding domain that binds to human CD3; and

a second binding domain that binds to human BCMA,

wherein the binding molecule has an EC₅₀of ≤5,000 pg/ml and greater than 5 pg/ml, when the EC₅₀is measured in a cell-based cytotoxicity assay comprising combining BCMA-positive human multiple myeloma L363 cells and unstimulated human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:10, incubating the combined L363 cells and PBMCs with the bispecific binding molecule, and performing a propidium iodide FACS assay after 48 hours of incubation.